Article

Pilot Study using Gabapentin for Tamoxifen-induced Hot Flashes in Women with Breast Cancer

James P. Wilmot Cancer Center, University of Rochester, Rochester, NY 14642 USA.
Breast Cancer Research and Treatment (Impact Factor: 3.94). 02/2004; 83(1):87-9. DOI: 10.1023/B:BREA.0000010676.54597.22
Source: PubMed

ABSTRACT

In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6% (P = 0.027), frequency of 44.2% (P < 0.001), and severity of 52.6% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.

1 Follower
 · 
8 Reads
  • Source
    • "HF duration decreased by 73.6% (p = 0.027) frequency by 44.2% (p < 0.001), and severity by 52.6% (p < 0.001). Four women dropped out due to AEs (nausea, rash, somnolence), while 8/16 women who finished the study showed a complete response (Pandya et al. 2004). A large study (Pandya et al. 2005) "
    [Show abstract] [Hide abstract]
    ABSTRACT: The cardinal climacteric symptoms of hot flushes and night sweats affect 24-93% of all women during the physiological transition from reproductive to post-reproductive life. Though efficacious, hormonal therapy and partial oestrogenic compounds are linked to a significant increase in breast cancer. Non-hormonal treatments are thus greatly appreciated. This systematic review of published hormonal and non-hormonal treatments for climacteric, and breast and prostate cancer-associated hot flushes, examines clinical efficacy and therapy-related cancer risk modulation. A PubMed search included literature up to June 19, 2014 without limits for initial dates or language, with the search terms, (hot flush* OR hot flash*) AND (clinical trial* OR clinical stud*) AND (randomi* OR observational) NOT review). Retrieved references identified further papers. The focus was on hot flushes; other symptoms (night sweats, irritability, etc.) were not specifically screened. Included were some 610 clinical studies where a measured effect of the intervention, intensity and severity were documented, and where patients received treatment of pharmaceutical quality. Only 147 of these references described studies with alternative non-hormonal treatments in post-menopausal women and in breast and prostate cancer survivors; these results are presented in Additional file 1. The most effective hot flush treatment is oestrogenic hormones, or a combination of oestrogen and progestins, though benefits are partially outweighed by a significantly increased risk for breast cancer development. This review illustrates that certain non-hormonal treatments, including selective serotonin reuptake inhibitors, gabapentin/pregabalin, and Cimicifuga racemosa extracts, show a positive risk-benefit ratio.
    Full-text · Article · Dec 2015 · SpringerPlus

  • No preview · Article ·
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung Die Hormonersatztherapie nach gynäkologischen Malignomen zur Behebung klimakterischer Beschwerden stellt eine klinische Herausforderung dar. Die Studienlage ist wenig weiter führend, überwiegend handelt es sich um inhomogene Fall-Kontroll-Studien mit geringen Fallzahlen. Unbedenklich scheint eine HRT nach Plattenepithelkarzinom der Zervix uteri sowie nach Vulva- und Vaginalkarzinomen zu sein. Bei Patientinnen nach Ovarialkarzinom muss die meist schlechte Gesamtprognose gegen den Erhalt der Lebensqualität abgewogen werden. Bei Patientinnen nach Endometriumkarzinom Stadium Ia und Ib scheint eine Östrogengabe weitgehend vertretbar zu sein. Der Sinn einer zusätzlichen Gestagengabe muss nach den jüngeren Studien zur Kombinationstherapie von Östrogenen und Gestagenen hinsichtlich des ungünstigen Risikoprofils einer solchen Therapie in Zweifel gezogen werden. Nach fortgeschrittenem Endometriumkarzinom und nach Mammakarzinom kann eine HRT nur als Individualentscheidung nach Versagen anderer Therapieoptionen und bei ausgeprägten klimakterischen Beschwerden in Betracht kommen. Als Therapiealternativen sind in erster Linie SSRI und SNRI zu nennen. Die Rolle des Tibolon und des Raloxifen ist bei nicht ausreichender Datenlage derzeit offen.
    No preview · Article · May 2005 · Gynäkologische Endokrinologie
Show more